Corrigendum to "Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's antiseizure efficacy" [Neuropharmacology 143 (2018) 186-204]
Neuropharmacology. 2018 Dec:143:349-350.
doi: 10.1016/j.neuropharm.2018.10.012.
Epub 2018 Oct 19.
1 Department of Pharmacology, Toxicology, and Pharmacy, University of Veterinary Medicine Hannover, Germany; Center for Systems Neuroscience, Hannover, Germany.
2 Program in Molecular and Integrative Biosciences, and Neuroscience Center (HiLife), University of Helsinki, Finland.
3 Institute for Organic Chemistry, Leibniz Universität Hannover, Germany.
4 Department of Pharmacology, Toxicology, and Pharmacy, University of Veterinary Medicine Hannover, Germany.
5 Department of Neuroscience, University of Copenhagen, Copenhagen, Denmark.
6 Department of Pharmacology, Toxicology, and Pharmacy, University of Veterinary Medicine Hannover, Germany; Center for Systems Neuroscience, Hannover, Germany. Electronic address: [email protected].